Payment overview · 2025
General Payments
$828.55
35 reported records · 14 companies
Healthcare provider profile · identity verified
Anton Furman, DO
Allopathic & Osteopathic Physicians|Family Medicine · LEVITTOWN, PA · NPI 1699167163
Verified facts
What the public records show
CMS Open Payments records show Anton Furman, DO received $828.55 in general payments during 2025 across 35 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Nuplazid, Paxlovid, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Nuplazid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1156 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $154.01 | 18.6% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $139.16 | 16.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $102.10 | 12.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.36 | 8.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.52 | 7.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.52 | 5.5% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $44.61 | 5.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $36.67 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.29 | 4.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.91 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.76 | 4.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.82 | 4.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.16 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.66 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $828.55 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $199.53 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $139.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $102.10 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $44.61 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $36.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.82 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 232 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 104 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
154 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1156 | 135 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
232 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1600 | 260 |
| Amlodipine Besylate | Amlodipine Besylate | 1181 | 205 |
| Eliquis | Apixaban | 1156 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1137 | 182 |
| Gabapentin | Gabapentin | 1064 | 146 |
| Furosemide | Furosemide | 933 | 164 |
| Sertraline Hcl | Sertraline Hcl | 855 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 795 | 149 |
| Metoprolol Succinate | Metoprolol Succinate | 790 | 132 |
| Lisinopril | Lisinopril | 650 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 598 | 88 |
| Losartan Potassium | Losartan Potassium | 588 | 105 |
| Metformin Hcl | Metformin Hcl | 585 | 103 |
| Famotidine | Famotidine | 556 | 102 |
| Escitalopram Oxalate | Escitalopram Oxalate | 554 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 554 | 101 |
| Mirtazapine | Mirtazapine | 543 | 94 |
| Donepezil Hcl | Donepezil Hcl | 528 | 90 |
| Trazodone Hcl | Trazodone Hcl | 501 | 103 |
| Quetiapine Fumarate | Quetiapine Fumarate | 480 | 69 |
| Potassium Chloride | Potassium Chloride | 469 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 389 | 56 |
| Carvedilol | Carvedilol | 370 | 55 |
| Omeprazole | Omeprazole | 349 | 80 |
| Memantine Hcl | Memantine Hcl | 334 | 52 |
| Divalproex Sodium | Divalproex Sodium | 315 | 44 |
| Buspirone Hcl | Buspirone Hcl | 303 | 48 |
| Simvastatin | Simvastatin | 271 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 61 |
| Alprazolam | Alprazolam | 263 | 60 |
| Gemtesa | Vibegron | 232 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 221 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 207 | 38 |
| Levetiracetam | Levetiracetam | 204 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 33 |
| Latanoprost | Latanoprost | 201 | 31 |
| Xarelto | Rivaroxaban | 199 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 46 |
| Methenamine Hippurate | Methenamine Hippurate | 188 | 18 |
| Valsartan | Valsartan | 181 | 30 |
| Farxiga | Dapagliflozin Propanediol | 179 | 25 |
| Warfarin Sodium | Warfarin Sodium | 178 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 174 | 68 |
| Fluoxetine Hcl | Fluoxetine Hcl | 172 | 22 |
| Montelukast Sodium | Montelukast Sodium | 170 | 28 |
| Allopurinol | Allopurinol | 168 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 162 | 50 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 159 | 24 |
| Tramadol Hcl | Tramadol Hcl | 159 | 67 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 158 | 154 |
| Midodrine Hcl | Midodrine Hcl | 154 | 28 |
| Myrbetriq | Mirabegron | 154 | 22 |
| Baclofen | Baclofen | 151 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 150 | 24 |
| Entresto | Sacubitril/Valsartan | 147 | 14 |
| Spironolactone | Spironolactone | 144 | 26 |
| Risperidone | Risperidone | 143 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 140 | 25 |
| Lorazepam | Lorazepam | 139 | 50 |
| Paroxetine Hcl | Paroxetine Hcl | 136 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 133 | 16 |
| Finasteride | Finasteride | 132 | 25 |
| Clonazepam | Clonazepam | 130 | 32 |
| Celecoxib | Celecoxib | 127 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 22 |
| Aripiprazole | Aripiprazole | 125 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 123 | 42 |
| Prednisone | Prednisone | 120 | 55 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 119 | 23 |
| Bumetanide | Bumetanide | 118 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 52 |
| Jantoven | Warfarin Sodium | 114 | suppressed |
| Ezetimibe | Ezetimibe | 113 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 71 |
| Jardiance | Empagliflozin | 111 | 21 |
| Nystatin | Nystatin | 109 | 45 |
| Rexulti | Brexpiprazole | 104 | 18 |
| Bupropion Xl | Bupropion Hcl | 102 | 17 |
| Atenolol | Atenolol | 100 | 16 |
| Torsemide | Torsemide | 100 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 97 | 15 |
| Cephalexin | Cephalexin | 92 | 51 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 91 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 14 |
| Nifedipine Er | Nifedipine | 88 | 16 |
| Budesonide | Budesonide | 87 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 51 |
| Methimazole | Methimazole | 78 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 76 | suppressed |
| Sucralfate | Sucralfate | 76 | 14 |
| Cefuroxime | Cefuroxime Axetil | 75 | 64 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 17 |
| Pregabalin | Pregabalin | 72 | 21 |
| Tradjenta | Linagliptin | 72 | suppressed |
| Loperamide | Loperamide Hcl | 71 | 44 |
| Repaglinide | Repaglinide | 71 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 13 |
| Glimepiride | Glimepiride | 70 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 68 | 18 |
| Amantadine | Amantadine Hcl | 67 | suppressed |
| Lamotrigine | Lamotrigine | 66 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 66 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 65 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 65 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 29 |
| Primidone | Primidone | 64 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 50 |
| Divalproex Sodium Er | Divalproex Sodium | 63 | suppressed |
| Olanzapine | Olanzapine | 63 | 17 |
| Glipizide Er | Glipizide | 62 | 13 |
| Novolog Flexpen | Insulin Aspart | 62 | 21 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Digoxin | Digoxin | 61 | suppressed |
| Azithromycin | Azithromycin | 60 | 39 |
| Milrinone In 5% Dextrose | Milrinone Lactate/D5w | 60 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 59 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 19 |
| Alendronate Sodium | Alendronate Sodium | 54 | suppressed |
| Ozempic | Semaglutide | 54 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 20 |
| Bupropion Hcl | Bupropion Hcl | 53 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 17 |
| Linzess | Linaclotide | 51 | 11 |
| Admelog Solostar | Insulin Lispro | 50 | suppressed |
| Nystop | Nystatin | 48 | 27 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 47 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Meloxicam | Meloxicam | 43 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 43 | suppressed |
| Brilinta | Ticagrelor | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Verapamil Er | Verapamil Hcl | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Lansoprazole | Lansoprazole | 38 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 38 | suppressed |
| Captopril | Captopril | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 37 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 37 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 19 |
| Creon | Lipase/Protease/Amylase | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | 16 |
| Prazosin Hcl | Prazosin Hcl | 35 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 34 | suppressed |
| Anastrozole | Anastrozole | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 19 |
| Nuplazid | Pimavanserin Tartrate | 34 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Risperidone Odt | Risperidone | 31 | suppressed |
| Erythromycin | Erythromycin Base | 30 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Desloratadine | Desloratadine | 29 | suppressed |
| Lactulose | Lactulose | 29 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 28 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 16 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Colchicine | Colchicine | 26 | 17 |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 25 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Nyamyc | Nystatin | 23 | 16 |
| Tiadylt Er | Diltiazem Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 21 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 21 | 20 |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 11 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Letrozole | Letrozole | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 18 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Silodosin | Silodosin | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Dofetilide | Dofetilide | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Levetiracetam Er | Levetiracetam | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $828.55 · 35 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, Auvelity, CAPLYTA, FANAPT, GEMTESA, INGREZZA, MOUNJARO, NUPLAZID, NURTEC ODT, PAXLOVID, REXULTI, TRELEGY ELLIPTA, VRAYLAR, VYNDAQEL, Veozah, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error